| Document |
Document Title |
|
JP2016155832A |
To provide an estrogen receptor modulator compound that is involved in a number of diseases and disorders, such as breast cancer, ovarian cancer, colon cancer, prostate cancer, endometrial cancer, uterine cancer, as well as other disease...
|
|
JP5982281B2 |
According to the invention there is provided a compound of formula (I) wherein: A represents C(═N—W-D) or S; B represents S or C(—NH—W-D); when: A represents C(═N—W-D) and B represents S then the bond between B and the NH ato...
|
|
JP5976733B2 |
In its many embodiments, the present invention provides provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds ster...
|
|
JP5972367B2 |
The present invention relates to a compound of formula (IA) The present invention also relates to the use of the compound of formula IA for treating certain neurodegenerative disorders characterized by cytotoxic TAU misfolding and/or agg...
|
|
JP2016523963A |
The present invention generally relates to compounds capable of inhibiting AAK1 (Adapter Associated Kinase 1), compositions containing such compounds, and methods of inhibiting AAK1.
|
|
JP5968213B2 |
|
|
JP2016134570A |
To provide an organic photoelectric conversion material which has sensitivity in a near infrared area.The organic photoelectric conversion material contains a compound expressed by the following general formula (1). (In the formula, Rto ...
|
|
JP2016128488A |
To provide inhibitors of cyclophilins having a selective inhibition activity for cyclophilin, for its use in the prevention and/or the treatment of viral pathologies or infections.The present invention relates to a compound represented b...
|
|
JP2016519674A |
The present invention comprises the substitutions N- (phenyl-heteroaryl) -3-acetylamino-benzamide and N- [3- (acetylamino) phenyl] -phenyl- of the general formula (I) described and defined herein. Heteroaryl-carboxamide, a method of prep...
|
|
JP5947724B2 |
The present invention relates to a compound of formula (I): wherein: n is 0, 1 or 2; A is in particular CH or N; X is in particular CO, SO2, CS, and R1 is in particular H, R2 is a group of formula NR3R4 or OR5, R3 and R4 being in particu...
|
|
JP5944483B2 |
Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11²-hydroxysteroid dehydrogenase typ...
|
|
JP2016518385A |
As the extermination-of-harmful-insects medicine to an animal and the internal parasitism living thing in humans in order that the present invention may control the nematodes in agriculture, Use of N* (phenyl cycloalkyl) Carboxamide and ...
|
|
JP5938364B2 |
A purpose of the present invention is to provide a new disulfide compound with excellent compatibility toward polymers containing fluorine and solutions containing fluorine. The compound of the present invention is a compound expressed b...
|
|
JP2016517412A |
The present invention relates to the compound for FASN prevention, constituents, those composition, application, and an antidote. An example of the compound of the present invention is shown below. [Drawing 1]
|
|
JP5934403B2 |
The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
|
|
JP2016104739A |
To provide an ionic compound useful as an ionic conducting material, an electron conducting material, a coloring agent and a catalyst for various chemical reactions and its use.There is provided an ion compound represented by the formula...
|
|
JP5931033B2 |
The present invention includes methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap ...
|
|
JP5928737B2 |
The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
|
|
JP5922027B2 |
Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatmen...
|
|
JP5911909B2 |
This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of uti...
|
|
JP5904944B2 |
The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions cont...
|
|
JP2016510781A |
Equation I [In equation, m, n, p, q, r, A, X1, X2, X3, X4, X5, X6, Y, Z, G, R1a, R2a, R1b, R2b, R3, R4, R5And R6Is as defined herein] or a pharmaceutically acceptable salt thereof. In addition, a method for producing a compound for treat...
|
|
JP2016028072A |
To provide a novel compound having a GPR40 activating action, particularly an insulin secretion promoter and an agent useful for prevention and/or therapy of diabetes, obesity, or the like.The present invention provides a compound of for...
|
|
JP5860045B2 |
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new s...
|
|
JP5840239B2 |
The present invention relates to an intermediate compound of modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"), compositions thereof which...
|
|
JP5829948B2 |
The invention provides compounds which contain or are capable of producing a methylol molecule in an aqueous environment, for use in inducing apoptotic death of a neoplastic cell, inhibiting growth of an autologous neoplastic cell in a m...
|
|
JP5827326B2 |
Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, p...
|
|
JP5823951B2 |
The present invention relates to bis-amide derivatives of formula (I), to processes and intermediates for preparing them, to methods of using them to control insect, acarine, nematode and mollusc pests, and to insecticidal, acaricidal, n...
|
|
JP2015205821A |
To provide a compound having excellent pest control efficacy to weeds.There is provided a cyclohexanone compound represented by the formula (I), where n represents any of 1 to 5, Rrepresents hydrogen or a methyl group, Rand Rrepresent hy...
|
|
JP5807971B2 |
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R5, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these c...
|
|
JP2015532279A |
The present invention has the formula (I).Provided are novel phenicol derivatives of, their use for the treatment of infectious diseases in mammals, pharmaceutical compositions containing such novel compounds, and methods of preparing su...
|
|
JP5801011B2 |
The problem to be solved is to provide a method for efficiently producing compounds (1) and (1a) that are important intermediate compounds in the production of FXa inhibitors (X) and (X-a). The solutions thereto are a method for producin...
|
|
JP5792619B2 |
The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein X1, R1, R2, R3, R4, and R5 are defined as set forth in the specification. The compounds are useful as potass...
|
|
JP5785354B2 |
The present invention relates to a method for identifying a glycemic stabilizing compound by: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is modulated, where a modulation in GPR41 functio...
|
|
JP5785491B2 |
wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG...
|
|
JP5782377B2 |
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone...
|
|
JP5778162B2 |
There is presently provided organic compounds of formula I, n-type acceptor materials derived from such compounds and devices comprising such n-type acceptor materials. (An-DprAn I
|
|
JP2015524483A |
To regulate benzene derivatives substituted with aryl and heteroaryl, pharmaceutical compositions containing them, and autophagy (or autophagy), or to block or reverse the PI3K-AKT-MTOR pathway. Provided are methods of slowing or inhibit...
|
|
JP5763621B2 |
Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug re...
|
|
JP5757666B2 |
This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of uti...
|
|
JP5756747B2 |
The present invention relates to hexafluoroisopropanol derivatives having the general formula I to pharmaceutical compositions comprising the same and to the use of these hexafluoroisopropanol derivatives in the treatment of atherosclero...
|
|
JP2015520748A |
The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates. A pharmaceutical composition containing the compound of formu...
|
|
JP2015129191A |
To provide new inhibitors for mitotic kinesin, more concretely, for the mitotic kinesin KSP, pharmaceutical compositions comprising the inhibitors, and methods for preparing the inhibitors.Provided are inhibitors for mitotic kinesin, con...
|
|
JP5746764B2 |
Compounds of formula (I) and formula (II) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which ...
|
|
JP5746860B2 |
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of the Formula (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and c...
|
|
JP5738204B2 |
|
|
JP2015091875A |
To provide modulators of ATP-Binding Cassette transporters.The present invention relates to the modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (...
|
|
JP5717750B2 |
The invention relates to alkylsulfide derivatives compounds of formula I as hereunder depicted or the enantiomers or veterinarily acceptable salts thereof which are useful for combating or controlling invertebrate pests, in particular ar...
|
|
JP5713352B2 |
The present invention relates to thiadiazolyloxyphenylamidines of the general formula (I), to a process for the preparation thereof, to the use of the amidines according to the invention in combating undesirable microorganisms and to a c...
|
|
JPWO2013031694A1 |
General formula "In the formula, R1 and R2 are the same or different, such as a halogen atom, a cyano group, a nitro group, an optionally substituted C1-6 alkyl group, etc .; R3 is an optionally substituted pyridyl group. , A monocyclic ...
|
